Interventional, multi-national, multi-center, prospective, randomized, open, blinded end-point registry-based clinical trial.

Patients with acute coronary syndrome undergoing coronary artery bypass grafting are postoperatively 1:1 randomized to receive therapy with ASA alone or ASA and ticagrelor for 1 year. In total, 2200 patients from twenty Nordic cardiac surgery centers will be included.

The primary endpoint is a combination of death, myocardial infarction, stroke and new revascularization during the first 12 months after randomization. Secondary endpoints are: individual major adverse cardiac events (MACE) elements, cardiovascular hospitalization, bleeding, dyspnoea, renal failure, atrial fibrillation, and MACE at 2, 3, 5 and 10 years.

To compare single antiplatelet therapy with acetylsalicylic acid (ASA) or dual antiplatelet therapy with ASA and ticagrelor after coronary artery bypass grafting in patients with acute coronary syndrome.

22 participating centres: Sweden (all 8), Denmark (all 4), Norway (4), Finnland (5), Iceland (1).

• Anders Jeppsson (Sponsor), Sahlgrenska University Hospital, Gothenborg, Sweden
• Ivy Susanne Modrau (institutional principal investigator), Aarhus University Hospital, Aarhus, Denmark

The Swedish Research Council (Vetenskapsrådet) and the Swedish Heart-Lung Foundation.

• Björklund E., Malm C. J., Nielsen S. J., Hansson E. C, Tygesen H., Romlin B. S., Martinsson A., Omerovic E., Pivodic A., Jeppsson A. Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome. JAMA Netw Open. 2021;4(8):e2122597. DOI: 10.1001/jamanetworkopen.2021.22597